PepGen Inc. has disclosed substantial stock transactions involving key investors in a recent filing. The report highlights the acquisition of 8.625 million shares by RA Capital Healthcare Fund LP, a significant move that underscores investor confidence in the company’s future.

This update is important as it reflects ongoing investment activity in the pharmaceutical preparations sector, a field characterized by rapid innovation and competition. The filing indicates that RA Capital Healthcare Fund LP and RA Capital Management, L.P. are actively managing their investments in PepGen, which could impact the company’s strategic decisions and market positioning.

Background

PepGen Inc. is a company focused on pharmaceutical preparations, classified under SIC code 2834. The firm trades on the Nasdaq under the ticker symbol PEPG. As an emerging growth company, PepGen is positioned to capitalize on advancements in the pharmaceutical industry.

What the Filing Says

The recent filing, dated November 17, 2026, reveals that RA Capital Healthcare Fund LP acquired 8.625 million shares at a price of $5 each on November 13, 2026. Following this transaction, RA Capital Healthcare Fund LP now holds a total of 27,179,273 shares in PepGen.

Impact

This acquisition may affect various stakeholders, including existing shareholders, employees, and potential investors. The significant ownership by RA Capital Healthcare Fund LP and other related entities suggests a strong belief in PepGen's potential for growth and innovation in the pharmaceutical sector.

What's Next

The filing does not say what happens next.